Daiichi Sankyo and Syneos Health link up on Enhertu and other cancer drugs

29 May 2020

Japanese drugmaker Daiichi Sankyo (TYO: 4568) and contract research organization Syneos Health (Nasdaq: SYNH) have formed a coalition to accomplish their shared goal of bringing promising cancer therapies to patients.

Under the agreement, Syneos Health will provide both strategic and operational solutions for three lead Daiichi Sankyo DXd antibody drug conjugates (ADC), DS-1062, U3-1402 and DS-8201.

The latter of the three is more commonly known as Enhertu (trastuzumab deruxtecan) and is a promising treatment for breast cancer and potentially other oncology indications that is being developed in partnership with Anglo-Swedish pharma major AstraZeneca (LSE: AZN).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK